PathAI Acquisition, Valuation, Funding & Investors

PathAI was acquired by Roche for $1.1B in May 2026.

PathAI acquisition price

$1.1B

Acquired by Roche · May 2026

Cumulative funding PathAI raised

$255M

across 5 funding rounds

Key investors in PathAI

  • General Catalyst
  • 8VC
  • DHVC
  • Pillar VC
  • Refactor
  • General Atlantic
  • D1 Capital Partners
  • Merck Global Health Innovation Fund

PathAI Overview

About PathAI

PathAI is a Boston-based provider of AI-powered pathology solutions founded in 2016. The platform automates tissue analysis for pharmaceutical research and clinical diagnostics, enabling precise cancer detection and drug development workflows. PathAI partners with biopharma leaders like Bristol Myers Squibb and integrates with major labs such as Quest Diagnostics across the United States and Europe. Its technology processes whole-slide images to quantify biomarkers, supporting over 40 clinical trials and routine pathology practices worldwide.


Founded

2016

HQ

United StatesBoston, MA

Website

pathai.com

Status

Acquired

Customer focus

B2B

Revenue model

Subscription

Valuation

$375M (Apr 2019)

PathAI Acquisition

PathAI was acquired by Roche for $1.1B on 6 May 2026.

Before the acquisition PathAI had raised $255M across 5 funding rounds.

Roche Holding AG entered into a definitive merger agreement to acquire PathAI, Inc. for up to $1.05 billion. The deal structure includes an upfront payment of $750 million and additional milestone payments of up to $300 million subject to targets. The transaction is expected to close in the second half of 2026, with PathAI integrating into Roche's Diagnostics division. The acquisition bolsters Roche's artificial-intelligence offerings in diagnostics, expanding AI-powered digital pathology and precision medicine capabilities. It aims to transform AI-driven diagnostics through PathAI's technology. PathAI is a U.S.-based digital pathology and AI company focused on diagnostics tools.

PathAI acquisition details
AcquirerDateTypePrice
6 May 2026Strategic M&A$1.1B

PathAI Valuation

PathAI is currently valued at $375M, based on its Series B in April 2019.

The $60M round was led by General Atlantic, with participation from General Catalyst and Innospark Ventures.

PathAI valuation by funding round

PathAI valuation by funding round
DateStageValuation
Apr 2019Series B$375M

PathAI Funding History

PathAI has raised a total of $255M across 5 funding rounds.

PathAI's first fundraising round was a $4M seed round in December 2016. The most recent completed round was a $165M Series C in May 2021.

PathAI funding rounds

PathAI funding rounds
DateStageInvestorsRaisedValuationDeal Summary
May 2021Series CD1 Capital Partners (lead); Kaiser Permanente (lead)$165M-PathAI is a Boston-based artificial intelligence company that provides AI-powered technology for pathology to improve the accuracy of disease diagnosis and treatment, particularly for cancer and other conditions. The company leverages machine learning and deep learning approaches to assist pathologists in making timely and accurate diagnoses and to identify ideal patients for clinical therapies. PathAI works with life sciences companies, pharmaceutical firms, and diagnostic partners including Bristol Myers Squibb, Labcorp, and Merck Global Health Innovation Fund. In May 2021, PathAI closed a Series C financing round of $165 million, co-led by D1 Capital Partners and Kaiser Permanente, a leading U.S. healthcare provider and not-for-profit health plan. The round also included participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, and Refactor Capital. PathAI planned to deploy the capital to accelerate product development, expand its suite of applications beyond oncology and nonalcoholic steatohepatitis, and strengthen partnerships with pharmaceutical and diagnostic organizations. With this Series C round, PathAI's total funding raised reached over $260 million. The company operated in a growing market, with the artificial intelligence in diagnostics sector projected to expand at a compound annual growth rate of 32.3% to reach $3 billion by 2027.
Nov 2019Series BLabcorp (lead); Merck Global Health Innovation Fund; Bristol-Myers Squibb$15M-PathAI develops artificial intelligence-powered technology for pathology research, using machine learning to improve diagnostic accuracy and treatment decisions by identifying disease biomarkers and predicting patient responses. The company secured a $15 million investment from Labcorp in November 2019, following its initial $60 million Series B round in April 2019 led by General Atlantic and General Catalyst. This extension brought the total Series B to $75 million, with participation from Bristol-Myers Squibb and Merck Global Health Innovation Fund. Labcorp's investment strengthened an ongoing collaboration to advance AI-enabled computational pathology for clinical applications. The funding supported PathAI's expansion of AI capabilities, market reach, and integration with clinical laboratories. PathAI, based in Boston, focused on applications in cancer diagnosis, nonalcoholic steatohepatitis, and beyond. The partnership with Labcorp aimed to accelerate digital pathology for faster, more accurate diagnoses and better patient outcomes.
Apr 2019Series BGeneral Atlantic (lead); General Catalyst; Innospark Ventures$60M$375MPathAI is a Boston-based company providing artificial intelligence-powered technology for pathology, aimed at improving disease diagnosis accuracy, particularly for cancer, through AI tools that assist pathologists and support pharmaceutical research and drug development. The Series B funding round on April 17, 2019, raised $60 million led by General Atlantic, with participation from General Catalyst and other existing investors including Innospark Ventures, to fuel expansion of its pathology platform, R&D into new tools, and scaling across disease areas globally. General Atlantic's Managing Director Dr. Michelle Dipp joined the board to advance PathAI's mission of faster, safer diagnostics. This initial Series B tranche was later extended, closing at $75 million in November 2019 with additional investments from Bristol-Myers Squibb and Merck Global Health Innovation Fund, followed by a $15 million extension led by LabCorp. The funding supported enhancements in clinical development, AI capabilities, and market reach. PathAI continued raising capital, reaching a $165 million Series C in 2021 co-led by D1 Capital Partners and Kaiser Permanente, with participation from prior investors like General Atlantic and General Catalyst, plus new ones including Tiger Global and strategic partners such as Labcorp and Merck, bringing total funding over $255 million. These funds expanded product offerings beyond oncology and NASH, grew commercial footprint, and enhanced drug development workflows for biopharma and labs. The company later made acquisitions like Poplar Healthcare and was acquired by Quest Diagnostics.
Nov 2017Series AGeneral Catalyst (lead); 8VC; Pillar VC; Refactor; KdT Ventures; DHVC$11M-PathAI develops AI-powered software to assist pathologists in diagnosing diseases more efficiently and accurately, particularly in pathology for cancer and other conditions. The company, founded in Cambridge, MA, focuses on machine learning applications to improve diagnostic precision and support precision medicine. In November 2017, PathAI raised $11 million in a Series A funding round led by General Catalyst, with participation from 8VC, Danhua Capital (DHVC), Pillar Companies (Pillar VC), Refactor Capital, and KdT Ventures. This brought total funding to $15 million following a prior seed round. General Catalyst's investment supported PathAI's early-stage growth in AI pathology technology. PathAI planned to use the proceeds to expand its team from 15 employees and advance development of its AI platform. The company added prominent board members, including Vertex Pharmaceuticals CEO Jeff Leiden and serial entrepreneur Stan Lapidus.
Dec 2016Seed8VC; Pillar VC; Refactor; DHVC; Fairhaven Capital Partners$4M-PathAI raised approximately $4.2 million in a seed round around 2016 from investors including 8VC, DHVC, Fairhaven Capital Partners, and Pillar VC. The company develops AI-powered pathology technology to improve diagnostics and drug development in healthcare.

Who has invested in PathAI?

14 investors have backed PathAI across its funding rounds, including General Catalyst, 8VC, DHVC, Pillar VC, Refactor and General Atlantic.

Lead investors include D1 Capital Partners, Kaiser Permanente, Labcorp, General Atlantic and General Catalyst.


PathAI Investors

Investors in PathAI by funding rounds participated
InvestorHQRoundsRoleFirst check
General CatalystUnited StatesSan Francisco, CA2LeadNov 2017
8VCUnited StatesSan Francisco, CA2ParticipantDec 2016
Pillar VCUnited StatesBoston, MA2ParticipantDec 2016
RefactorUnited StatesSan Francisco, CA2ParticipantDec 2016
DHVCUnited StatesSan Francisco, CA2ParticipantDec 2016
Innospark VenturesUnited StatesBoston, MA1ParticipantApr 2019
KdT VenturesUnited StatesAustin, TX1ParticipantNov 2017
LabcorpUnited StatesUnited States1LeadNov 2019
Merck Global Health Innovation FundUnited StatesWoodcliff Lake, NJ1ParticipantNov 2019
General AtlanticUnited StatesNew York City, NY1LeadApr 2019
Bristol-Myers SquibbUnited StatesNew York City, NY1ParticipantNov 2019
Kaiser PermanenteUnited StatesSan Francisco, CA1LeadMay 2021

This data is available for Pro users. Sign up to see all 14 PathAI investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by PathAI

PathAI has acquired 1 company to date.

Last acquisition by PathAI was on July 26th 2021. PathAI acquired Poplar Healthcare for undisclosed valuation.


Latest Acquisitions by PathAI

Poplar Healthcare
Description
Poplar Healthcare is a Memphis-headquartered laboratory services provider operating specialized brands including GI Pathology, D-PATH Dermatopathology, OncoMetrix, UroPath Diagnostics, and Women’s Health Laboratories. It delivers anatomic pathology testing to gastroenterologists, dermatologists, oncologists, urologists, and gynecologists nationwide. The company processes biopsies and specimens from clinics across the United States, supporting clinical decisions with rapid turnaround diagnostics.
HQ CountryUnited States
HQ City
Memphis, TN
Deal Date26 Jul 2021
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all PathAI acquisitions and their M&A valuation multiples.

Start Free Trial

PathAI Competitors

PathAI competitors include listed companies like IDEXX Laboratories and PHC Holdings, and private ones like BrightInsight, Dental Monitoring, AcuityMD and Helian Health.

Public and private companies comparable to PathAI
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
BrightInsightUnited StatesSan Francisco, CAPrivate--$750M-
IDEXX LaboratoriesUnited StatesUnited StatesPublicly listed$4.3B$1.5B$40B8.9x
PHC HoldingsJapanJapanPublicly listed$2.3B$320M$1.1B1.0x
Dental MonitoringFranceParisPrivate$91M-$1B-
AcuityMDUnited StatesBoston, MAPrivate--$955M-
Helian HealthChinaHangzhouPrivate--$900M-

PathAI Public Comps

PathAI is no longer listed, but its public comps include Vitec Software, iFLYHealth, PHC Holdings, Castle Biosciences, HealthStream, OPKO Health, MedicalSystem Technology, Novogene, Eckert & Ziegler and U.S. Physical Therapy.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Vitec Software$371M$151M3.7x3.5x9.1x9.0x
iFLYHealth$136M($7M)7.7x6.2x(150.8x)(144172.5x)
PHC Holdings$2.3B$320M1.0x1.0x7.2x6.5x
Castle Biosciences$344M($429K)2.6x2.5x(2082.6x)44.9x
HealthStream$304M$63M2.8x2.6x13.2x11.2x
OPKO Health$607M($56M)2.2x2.3x(23.3x)(11.2x)
MedicalSystem Technology$45M$12M18.9x15.6x70.7x62.9x
Novogene$329M$50M1.9x1.9x12.5x13.5x

This data is available for Pro users. Sign up to see all PathAI competitors and their valuation data.

Start Free Trial

Common questions about PathAI

When was PathAI founded?PathAI was founded in 2016.
Where is PathAI headquartered?PathAI is headquartered in Boston, MA, United States.
Is PathAI publicly listed?No, PathAI was acquired by Roche in May 2026.
Who acquired PathAI?PathAI was acquired by Roche in May 2026.
How much was PathAI acquired for?PathAI was acquired for $1.1B in May 2026.
What is PathAI's valuation?PathAI was last valued at $375M in its Series B in April 2019.
How much funding has PathAI raised?PathAI has raised $255M across 5 funding rounds.
What was PathAI's last funding round?PathAI's last funding round was a $165M Series C in May 2021, led by D1 Capital Partners and Kaiser Permanente.
Who are PathAI's investors?PathAI's investors include General Catalyst, 8VC, Pillar VC, Refactor, DHVC, Innospark Ventures, KdT Ventures, Labcorp, Merck Global Health Innovation Fund, General Atlantic and 4 others.
Which companies are comparable to PathAI?Companies comparable to PathAI include BrightInsight, IDEXX Laboratories, PHC Holdings, Dental Monitoring, AcuityMD and Helian Health.
How many companies has PathAI acquired?PathAI has acquired 1 company, including Poplar Healthcare.

See companies similar to PathAI

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial